Pantomylan (Pantoprazole)

Pantoprazole, the active ingredient in Pantomylan, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is employed in the management of acid‑related disorders such as gastro‑esophageal reflux disease, erosive esophagitis, peptic ulcer disease, Helicobacter pylori eradication regimens, and Zollinger‑Ellison syndrome.

GNH USA supplies Pantomylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other health‑care institutions worldwide, with reliable logistics and quality assurance, ensuring timely delivery to global markets.

Pantoprazole is a proton pump inhibitor used to manage conditions associated with excess gastric acid secretion.

- Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Erosive esophagitis: facilitates mucosal repair and decreases further acid damage. - Peptic ulcer disease: accelerates ulcer healing and prevents recurrence. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic combinations. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid in this rare endocrine disorder.

Pantoprazole may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhea: loose stools that usually resolve without intervention. - Nausea: occasional feeling of queasiness, especially after initiation. - Abdominal pain: mild discomfort or cramping.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of rash, swelling, and breathing difficulty. - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Low magnesium levels (hypomagnesemia): may cause muscle cramps, arrhythmias, or seizures.

Before prescribing Pantoprazole, clinicians should consider several safety aspects.

- Assess renal function: evaluate kidney status prior to initiation, especially in severe impairment. - Monitor magnesium: check serum magnesium during prolonged therapy to avoid deficiency. - Avoid abrupt discontinuation: taper the dose to prevent rebound acid hypersecretion. - Use with caution in hepatic impairment: dose adjustment may be required for significant liver disease. - Inform about drug absorption: advise patients that acid‑dependent drugs (e.g., ketoconazole) may have reduced absorption. - Store at ambient temperature: keep below 25 °C, retain in the original container, and protect from moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased antiviral absorption, compromising HIV therapy. - High‑dose methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible elevation of INR, requiring more frequent monitoring. - Digoxin: altered serum concentrations, may need dose adjustment. - Diazepam: increased plasma levels, potentially enhancing sedation.